CN107501258A - 一种噻唑基烟酰胺类化合物及其在制备抗过敏和哮喘药物中的应用 - Google Patents
一种噻唑基烟酰胺类化合物及其在制备抗过敏和哮喘药物中的应用 Download PDFInfo
- Publication number
- CN107501258A CN107501258A CN201710828917.4A CN201710828917A CN107501258A CN 107501258 A CN107501258 A CN 107501258A CN 201710828917 A CN201710828917 A CN 201710828917A CN 107501258 A CN107501258 A CN 107501258A
- Authority
- CN
- China
- Prior art keywords
- thiazolyl
- prepared
- methyl
- formula
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 229960003966 nicotinamide Drugs 0.000 title claims abstract description 16
- 239000011570 nicotinamide Substances 0.000 title claims abstract description 16
- 235000005152 nicotinamide Nutrition 0.000 title claims abstract description 13
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 title claims abstract description 13
- -1 thiazolyl nicotinamide compound Chemical class 0.000 title claims abstract description 11
- 208000006673 asthma Diseases 0.000 title abstract description 14
- 230000003266 anti-allergic effect Effects 0.000 title abstract description 6
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 12
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 6
- 239000000739 antihistaminic agent Substances 0.000 claims abstract description 5
- 229940124623 antihistamine drug Drugs 0.000 claims abstract description 4
- 201000010099 disease Diseases 0.000 claims abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 4
- 230000001088 anti-asthma Effects 0.000 claims description 7
- 208000003251 Pruritus Diseases 0.000 claims description 5
- 206010012434 Dermatitis allergic Diseases 0.000 claims description 3
- 208000024780 Urticaria Diseases 0.000 claims description 3
- 201000008937 atopic dermatitis Diseases 0.000 claims description 3
- 208000010668 atopic eczema Diseases 0.000 claims description 3
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 2
- 239000000924 antiasthmatic agent Substances 0.000 claims description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 10
- 229940122236 Histamine receptor antagonist Drugs 0.000 abstract description 3
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 2
- 208000026935 allergic disease Diseases 0.000 abstract description 2
- 230000007815 allergy Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 238000011835 investigation Methods 0.000 abstract 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 24
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical class CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical class ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 20
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 20
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 20
- 125000000335 thiazolyl group Chemical group 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 18
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- 229960001340 histamine Drugs 0.000 description 10
- 210000003405 ileum Anatomy 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 238000005160 1H NMR spectroscopy Methods 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 239000000370 acceptor Substances 0.000 description 6
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 5
- 241000700199 Cavia porcellus Species 0.000 description 5
- 239000007832 Na2SO4 Substances 0.000 description 5
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 229960001271 desloratadine Drugs 0.000 description 4
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- JBIMVDZLSHOPLA-LSCVHKIXSA-N olopatadine Chemical compound C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 JBIMVDZLSHOPLA-LSCVHKIXSA-N 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 2
- 229960004754 astemizole Drugs 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Natural products O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- PPZMYIBUHIPZOS-UHFFFAOYSA-N histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 2
- 229960000645 histamine hydrochloride Drugs 0.000 description 2
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 2
- 229960004114 olopatadine Drugs 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- RXTRRIFWCJEMEL-UHFFFAOYSA-N 2-chloropyridine-3-carbonyl chloride Chemical class ClC(=O)C1=CC=CN=C1Cl RXTRRIFWCJEMEL-UHFFFAOYSA-N 0.000 description 1
- CSQKICWPCREIJP-UHFFFAOYSA-N 4-chloropyridine-3-carbonyl chloride Chemical class ClC(=O)C1=CN=CC=C1Cl CSQKICWPCREIJP-UHFFFAOYSA-N 0.000 description 1
- FMEBIWNKYZUWFV-UHFFFAOYSA-N 6-chloropyridine-3-carbonyl chloride Chemical class ClC(=O)C1=CC=C(Cl)N=C1 FMEBIWNKYZUWFV-UHFFFAOYSA-N 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- 229920005479 Lucite® Polymers 0.000 description 1
- HVRLZEKDTUEKQH-NOILCQHBSA-N Olopatadine hydrochloride Chemical compound Cl.C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 HVRLZEKDTUEKQH-NOILCQHBSA-N 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000001243 acetic acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229940008201 allegra Drugs 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000002804 anti-anaphylactic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940058060 astelin Drugs 0.000 description 1
- 229960004574 azelastine Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- 229940119122 clarinex Drugs 0.000 description 1
- 229940088529 claritin Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940112573 elestat Drugs 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960003449 epinastine Drugs 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000003694 hair properties Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229940061037 optivar Drugs 0.000 description 1
- 229940090118 patanase Drugs 0.000 description 1
- 229940097078 patanol Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000036316 preload Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- ATBIAJXSKNPHEI-UHFFFAOYSA-N pyridine-3-carbonyl chloride Chemical compound ClC(=O)C1=CC=CN=C1 ATBIAJXSKNPHEI-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940036139 zyrtec Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
Description
Claims (7)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710828917.4A CN107501258B8 (zh) | 2017-09-14 | 2017-09-14 | 一种噻唑基烟酰胺类化合物及其在制备抗过敏和哮喘药物中的应用 |
CN201810421668.1A CN108299418A (zh) | 2017-09-14 | 2017-09-14 | 一种抗过敏和哮喘的噻唑基烟酰胺类化合物的合成方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710828917.4A CN107501258B8 (zh) | 2017-09-14 | 2017-09-14 | 一种噻唑基烟酰胺类化合物及其在制备抗过敏和哮喘药物中的应用 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810421668.1A Division CN108299418A (zh) | 2017-09-14 | 2017-09-14 | 一种抗过敏和哮喘的噻唑基烟酰胺类化合物的合成方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
CN107501258A true CN107501258A (zh) | 2017-12-22 |
CN107501258B CN107501258B (zh) | 2018-08-28 |
CN107501258B8 CN107501258B8 (zh) | 2018-10-16 |
Family
ID=60696748
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710828917.4A Expired - Fee Related CN107501258B8 (zh) | 2017-09-14 | 2017-09-14 | 一种噻唑基烟酰胺类化合物及其在制备抗过敏和哮喘药物中的应用 |
CN201810421668.1A Withdrawn CN108299418A (zh) | 2017-09-14 | 2017-09-14 | 一种抗过敏和哮喘的噻唑基烟酰胺类化合物的合成方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810421668.1A Withdrawn CN108299418A (zh) | 2017-09-14 | 2017-09-14 | 一种抗过敏和哮喘的噻唑基烟酰胺类化合物的合成方法 |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN107501258B8 (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1527830A (zh) * | 2001-01-31 | 2004-09-08 | �Ʒ� | 用作pde4同工酶的抑制剂的醚衍生物 |
CN1914205A (zh) * | 2003-12-19 | 2007-02-14 | 葛兰素集团有限公司 | 吡唑并[3,4-b]吡啶化合物及其作为磷酸二酯酶抑制剂的用途 |
WO2010056875A1 (en) * | 2008-11-12 | 2010-05-20 | Cgi Pharmaceuticals, Inc. | Pyridazinones and their use as btk inhibitors |
WO2013063385A1 (en) * | 2011-10-28 | 2013-05-02 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
TWI444370B (zh) * | 2006-01-25 | 2014-07-11 | Synta Pharmaceuticals Corp | 用於發炎及免疫相關用途之噻唑及噻二唑化合物 |
CN106905311A (zh) * | 2010-08-27 | 2017-06-30 | 钙医学公司 | 调节细胞内钙的化合物 |
-
2017
- 2017-09-14 CN CN201710828917.4A patent/CN107501258B8/zh not_active Expired - Fee Related
- 2017-09-14 CN CN201810421668.1A patent/CN108299418A/zh not_active Withdrawn
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1527830A (zh) * | 2001-01-31 | 2004-09-08 | �Ʒ� | 用作pde4同工酶的抑制剂的醚衍生物 |
CN1914205A (zh) * | 2003-12-19 | 2007-02-14 | 葛兰素集团有限公司 | 吡唑并[3,4-b]吡啶化合物及其作为磷酸二酯酶抑制剂的用途 |
TWI444370B (zh) * | 2006-01-25 | 2014-07-11 | Synta Pharmaceuticals Corp | 用於發炎及免疫相關用途之噻唑及噻二唑化合物 |
WO2010056875A1 (en) * | 2008-11-12 | 2010-05-20 | Cgi Pharmaceuticals, Inc. | Pyridazinones and their use as btk inhibitors |
CN106905311A (zh) * | 2010-08-27 | 2017-06-30 | 钙医学公司 | 调节细胞内钙的化合物 |
WO2013063385A1 (en) * | 2011-10-28 | 2013-05-02 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
Also Published As
Publication number | Publication date |
---|---|
CN108299418A (zh) | 2018-07-20 |
CN107501258B8 (zh) | 2018-10-16 |
CN107501258B (zh) | 2018-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2006215080B2 (en) | Pyridyl non-aromatic nitrogenated heterocyclic-1-carboxylate ester derivative | |
NO314580B1 (no) | 4-substituerte piperidinanaloger, farmasöytisk preparat og deres anvendelsefor fremstilling av et medikament for behandling av sykdommer somreagerer på selektiv blokade av N-metyl-D-aspartatreseptorsubtyper | |
KR102117453B1 (ko) | 5-아릴알키닐기에 의해 치환된 벤즈아미드계 화합물 및 이의 제조방법, 약물 조성물과 용도 | |
CN106103422A (zh) | 异喹啉衍生物及其用途 | |
CN105254557A (zh) | 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物 | |
CN103025716B (zh) | 二环化合物衍生物及其作为acc抑制剂的用途 | |
WO2001051469A1 (de) | Piperidin- und piperazinderivate als 5-ht2a rezeptor antagonisten | |
EP2351749A1 (en) | Carbamate compound or salt thereof | |
KR102556482B1 (ko) | 테트라히드로이소퀴놀린계 화합물, 이의 제조 방법, 테트라히드로이소퀴놀린계 화합물을 포함하는 약물 조성물 및 이의 용도 | |
CN106414438A (zh) | 2‑酰氨基噻唑衍生物或其盐 | |
CN106854207B (zh) | 呔嗪类衍生物、其制备方法、药物组合物和用途 | |
CN107108587A (zh) | 醛固酮合成酶抑制剂 | |
CN107793408A (zh) | 哌啶氨基衍生物及其治疗精神分裂症的应用 | |
AU2005268899B2 (en) | Substituted N-acyl-2-aminothiazoles | |
CN107501251A (zh) | 一种化合物及其在制备抗过敏药物中的应用 | |
DE60216310T2 (de) | Substituierte 4-phenyl-4-(1h-imidazol-2-yl)-piperidinderivate zur verringerung von ischämischer schädigung | |
CN107501258B (zh) | 一种噻唑基烟酰胺类化合物及其在制备抗过敏和哮喘药物中的应用 | |
NO312726B1 (no) | Enterokinetisk benzamid | |
DE60009287T2 (de) | Neuartige isoquinolin-derivate oder salze davon | |
NO317649B1 (no) | Optisk aktiv pyridyl-4H-1,2,4-oksazdiazinderivat og dets anvendelse ved behandling av karsykdommer | |
CN107400124A (zh) | 一种烟酰胺类化合物、合成路线及其在制备抗过敏药物中的应用 | |
CN107573337A (zh) | 一种化合物、制备方法及其在制备治疗过敏和哮喘药物中的应用 | |
CN107522694A (zh) | 一种烟酰胺类化合物、合成路线及其在制备抗过敏和哮喘药物中的应用 | |
CN102627631B (zh) | 苯并杂环类化合物、其制备方法及其医药用途 | |
EP0879234A1 (de) | 1-(pyrazol-3-yl-ethyl)-4-(indol-3-yl)-piperidine als das zentralnervensystem beeinflussende mittel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Dong Zehua Inventor after: Liu Shuangwei Inventor before: Liu Shuangwei |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180828 Address after: 266071 16 Jiangsu Road, Shinan District, Qingdao, Shandong Patentee after: THE AFFILIATED HOSPITAL OF QINGDAO University Address before: 262610 Yueyang Zhuang medicine research base, Xin Zhai Town, Linqu County, Weifang, Shandong Patentee before: Liu Shuangwei |
|
CI03 | Correction of invention patent | ||
CI03 | Correction of invention patent |
Correction item: Patentee|Address|Inventor|Patent agency|Agent Correct: Affiliated Hospital of University Of Qingdao|266071 16 Jiangsu Road, Shinan District, Qingdao, Shandong|Dong Zehua, Liu Shuangwei|Qingdao Hua Hui patent agency (general partnership) 37247|Qu Xianrong, Ma Qian Hui False: Liu Shuangwei|262610 Yueyang Zhuang medicine research base, Xin Zhai Town, Linqu County, Weifang, Shandong|Liu Shuangwei|N/A Number: 35-01 Volume: 34 Correction item: Patentee|Address|Inventor|Patent agency|Agent Correct: Affiliated Hospital of University Of Qingdao|266071 16 Jiangsu Road, Shinan District, Qingdao, Shandong|Dong Zehua, Liu Shuangwei|Qingdao Hua Hui patent agency (general partnership) 37247, Qu Xianrong, Ma Qian Hui False: Liu Shuangwei|262610 Yueyang Zhuang medicine research base, Xin Zhai Town, Linqu County, Weifang, Shandong|Liu Shuangwei|N/A Number: 35-01 Page: The title page Volume: 34 |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180828 Termination date: 20210914 |
|
CF01 | Termination of patent right due to non-payment of annual fee |